BNET Industries
Market Cap:$147.2B
Last Fiscal Year Sales:$48.4B
- Public
- US
Dow Jones Description
Taking care of you and your four-legged friends too! Pfizer Inc. (NYSE: PFE), based in New York, NY, discovers, develops, manufactures and sells prescription medications for humans and animals. Employing about 115,000 people, this $51.3 billion company operates in three segments: Human Health, Consumer Healthcare and Animal Health. Together, these segments cover treatments for diseases such as cardiovascular and metabolic diseases, medications for oral care, tobacco dependence, and products for prevention and treatment of diseases in livestock and pets.
Number of Employees 81,800
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Can Roche Leave Genentech Alone?
-
Pfizer PFE Will Not Renew Ethical Distribution Agreement Term with MWI Veterinary Supply MWIV
-
Pfizer Inc. and Wyeth; Analysis of Agreement Containing Consent Order To Aid Public Comment and...
-
A 2nd Loss for Pfizer in Drug Suits
-
Pfizer acquires stem cell therapies assets of Axordia
-
Standpoint Raised Its FY10 Price Target on Pfizer PFE to $24
-
ImmunoVaccine signs exclusive licence deal with Pfizer
-
Pfizer Animal Health selects Bader Rutter as agency of record
-
FDA panel backs Pfizer's anti-infection vaccine for kids
-
Cash Just Kept On Piling Up, But It Looks Like The Spending Has Started
-
Goldman Sachs Said Pfizer PFE Best Positioned US Pharma in China
-
EDITORIAL: Difficult mix of business, science
-
$75M verdict unsealed in Prempro-cancer case
-
Sanofi-Aventis on hunt for Boston partners
-
Pfizer says in partnership deal with BMP in China
-
Pfizer Inc. PFE Says in Partnership Deal with BMP Sunstone in China
-
Still Enjoying Those Acquisitions, Pfizer?
-
Status Of Pfizer And Wyeth Research Facilities
-
Monsanto MON Agrees to Acquire Pfizer's PFE Chesterfield Village Research Center for $435M
News & Analysis
Filter by
pfizer inc. and schering-plough corp. - All News and Analysis
Why I'm Shifting Portfolio Sector Weightings
Seeking Alpha
- 2009-07-01
Ryan Barnes submits: This morning there’s going to be some big changes to the Secular Trends Portfolio; as stated earlier there’s far too much cash sitting around. There are several themes that deserve representation, and a few sectors where the level of underweight (compared to the S&P 500) is more...
Pharma Roundup: Schering-Plough's $500,000 Bonus, Bristol and Exelixis, and More
BNET
- 2008-12-12
Cash-strapped Schering-Plough gives out $500,000 bonus; Bristol-Myers Squibb buys chunk of Exelixis pipeline; Pfizer and Elan cut jobs. by John Maas
Pharma Roundup: Schering-Plough's Pipeline, Pfizer's Pipeline, and More
BNET
- 2008-11-24
Schering-Plough claims robust pipeline; Pfizer's pipeline grows steadily; King finally owns Alpharma; Johnson & Johnson owns Omrix. by John Maas
Pharma Roundup: Schering-Plough Pays Missouri, 12 Pfizer Execs Announced, and More
BNET
- 2008-10-31
Schering-Plough reaches settlement with Missouri; executive announcements at Pfizer; four CEOS talk to BusinessWeek by John Maas
Summer Surge for Pharma Powers IHE, but Concerns Remain
Seeking Alpha
- 2008-09-11
Don Dion submits: Buoyed by some consolidation and seen as a safe haven in an uncertain market, healthcare stocks rallied hard in July and held their momentum into August. The sector cooled some during the last few weeks, but the S&P 500’s healthcare companies were still up...
Fannie, Freddie & Pharma: Does Resolution Help Sector Stocks?
Seeking Alpha
- 2008-09-09
Mike Huckman submits: So, what the heck does pharma have to do with mortgage giants Fannie FNM and Freddie FRE and the government's action to save them? John Sullivan, the Director of Research at Leerink Swann, which specializes in healthcare stocks, says there is a potential trading opportunity in...
Tough Projections for Big Pharmas: Drug Revenues Don't Look Promising
Seeking Alpha
- 2008-08-21
Derek Lowe submits: Well, today’s subject isn’t a cheerful data set, but it certainly deserves some thought. Over at Pharmalot, Ed Silverman has some data from consulting firm AVOS Life Sciences, which has sat down to estimate how well various drug companies will do with revenue from new drugs...
Time to Invest in Pharmaceuticals?
Seeking Alpha
- 2008-08-17
Howard Sun submits: The prices of many pharmaceutical companies have been beaten down by Wall Street in recent months. With companies like Pfizer PFE, Schering-Plough SGP and Bristol-Myers Squibb BMY reaching lower lows, one has to wonder when the pain will end as these companies are now significantly undervalued. The...
Are Big Pharma's Dollar Days Nearly Over?
Seeking Alpha
- 2008-08-13
Mike Huckman submits: For quite some time now the major American pharmaceutical companies have been benefiting from the foreign exchange rate. Besides cost-cutting, the weak dollar has been propping up revenue and profits during a time when the sector is battling intense competition from much cheaper generic drugs, safety...
PowerShares FTSE RAFI Healthcare: Big Bets on Dow Dogs
Seeking Alpha
- 2008-07-31
Don Dion submits: While the PowerShares FTSE RAFI Health Care fund PRFH has experienced a recent leap in momentum, this move may not come as a surprise to many health care investors. PRFH has jumped 20 spots, from 61 to 41, on our PowerShares Momentum Tracker Sector Momentum...
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
